These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 9916753)
1. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6. Delgado M; Martinez C; Pozo D; Calvo JR; Leceta J; Ganea D; Gomariz RP J Immunol; 1999 Jan; 162(2):1200-5. PubMed ID: 9916753 [TBL] [Abstract][Full Text] [Related]
2. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies. Delgado M; Pozo D; Martinez C; Leceta J; Calvo JR; Ganea D; Gomariz RP J Immunol; 1999 Feb; 162(4):2358-67. PubMed ID: 9973516 [TBL] [Abstract][Full Text] [Related]
3. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D J Immunol; 1999 Feb; 162(3):1707-16. PubMed ID: 9973433 [TBL] [Abstract][Full Text] [Related]
4. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation. Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D J Immunol; 1999 Apr; 162(8):4685-96. PubMed ID: 10202009 [TBL] [Abstract][Full Text] [Related]
5. The vasoactive peptide maxadilan from sand fly saliva inhibits TNF-alpha and induces IL-6 by mouse macrophages through interaction with the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor. Soares MB; Titus RG; Shoemaker CB; David JR; Bozza M J Immunol; 1998 Feb; 160(4):1811-6. PubMed ID: 9469441 [TBL] [Abstract][Full Text] [Related]
6. Neuropeptides as modulators of macrophage functions. Regulation of cytokine production and antigen presentation by VIP and PACAP. Ganea D; Delgado M Arch Immunol Ther Exp (Warsz); 2001; 49(2):101-10. PubMed ID: 11348014 [TBL] [Abstract][Full Text] [Related]
7. Vasoactive Intestinal Peptide and pituary adenylate cyclase-activating polypeptide inhibit tissue factor expression in monocyte in vitro and in vivo. Lv B; Tang Y; Chen F; Xiao X Shock; 2009 Feb; 31(2):185-91. PubMed ID: 18650785 [TBL] [Abstract][Full Text] [Related]
8. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide-38 inhibit IL-10 production in murine T lymphocytes. Martinez C; Delgado M; Gomariz RP; Ganea D J Immunol; 1996 Jun; 156(11):4128-36. PubMed ID: 8666779 [TBL] [Abstract][Full Text] [Related]
9. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells. Nagakawa O; Junicho A; Akashi T; Koizumi K; Matsuda T; Fuse H; Saiki I Oncol Rep; 2005 Jun; 13(6):1217-21. PubMed ID: 15870945 [TBL] [Abstract][Full Text] [Related]
10. Anorexigenic effects of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide in the chick brain are mediated by corticotrophin-releasing factor. Tachibana T; Saito ES; Takahashi H; Saito S; Tomonaga S; Boswell T; Furuse M Regul Pept; 2004 Aug; 120(1-3):99-105. PubMed ID: 15177926 [TBL] [Abstract][Full Text] [Related]
11. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia. Delgado M; Jonakait GM; Ganea D Glia; 2002 Aug; 39(2):148-61. PubMed ID: 12112366 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo. Delgado M; Ganea D J Immunol; 2001 Jul; 167(2):966-75. PubMed ID: 11441105 [TBL] [Abstract][Full Text] [Related]
13. Analysis of the role of the PAC1 receptor in neutrophil recruitment, acute-phase response, and nitric oxide production in septic shock. Martínez C; Juarranz Y; Abad C; Arranz A; Miguel BG; Rosignoli F; Leceta J; Gomariz RP J Leukoc Biol; 2005 May; 77(5):729-38. PubMed ID: 15661828 [TBL] [Abstract][Full Text] [Related]
14. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia. Delgado M; Leceta J; Ganea D J Leukoc Biol; 2003 Jan; 73(1):155-64. PubMed ID: 12525573 [TBL] [Abstract][Full Text] [Related]
15. VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression. Delgado M; Sun W; Leceta J; Ganea D J Immunol; 1999 Oct; 163(8):4213-23. PubMed ID: 10510358 [TBL] [Abstract][Full Text] [Related]
16. PACAP inhibit the release and cytokine activity of HMGB1 and improve the survival during lethal endotoxemia. Tang Y; Lv B; Wang H; Xiao X; Zuo X Int Immunopharmacol; 2008 Dec; 8(12):1646-51. PubMed ID: 18713653 [TBL] [Abstract][Full Text] [Related]
17. Shedding of membrane-bound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide. Delgado M; Leceta J; Abad C; Martinez C; Ganea D; Gomariz RP J Neuroimmunol; 1999 Sep; 99(1):61-71. PubMed ID: 10496178 [TBL] [Abstract][Full Text] [Related]
18. [Neuroprotective effects of novel derivatives of vasoactive intestinal peptide and pituitary adenylate cyclase-activating peptide in two brain ischemic models on mice]. Takeda N; Murozono M; Watanabe S; Isshiki A; Watanabe Y Masui; 2005 Mar; 54(3):240-8. PubMed ID: 15794099 [TBL] [Abstract][Full Text] [Related]